Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cetuximab + irinotecan every second week in irinotecan-resistant metastatic colorectal cancer
2006-001961-40Phase 2Completed
- Sponsor
- Department of Oncology, Herlev University Hospital
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and irinotecan in metastatic colon cancer (mCRC), sponsored by Department of Oncology, Herlev University Hospital. Primary endpoint: Overall response rate. Started Jun 2006; status: completed.
02
Drugs
cetuximabirinotecan
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2006-001961-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001961-40.